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The p53-Mdm2 network
In response to cellular stresses such as DNA damage or
oncogene activation, the tumor suppressor protein p53
becomes stabilized and modulates transcription of target genes
(Vousden and Lu, 2002). These drive a variety of cellular
responses to stress, including DNA repair, cell-cycle arrest,
senescence and apoptosis. Key targets are the proapoptotic
genes Bax, Puma and Noxa (Michalak et al., 2005), the genes
encoding the cell cycle regulators p21 (el-Deiry et al., 1993)
and Ptprv (Doumont et al., 2005) and the senescence-inducing
gene Plasminogen activator inhibitor 1 (Kortlever et al., 2006).
In the absence of stress signals, the activity of the p53
protein is kept in check to allow normal cell proliferation and
to maintain cell viability. Crucially important for this process
is the product of the murine double minute gene Mdm2. Mdm2
was originally identified by virtue of its amplification in a
spontaneously transformed mouse BALB/c cell line (3T3-DM)
(Cahilly-Snider et al., 1987). Momand et al. later reported that
Mdm2 physically associates with p53 and inhibits p53-
mediated transcriptional activation (Momand et al., 1992),
providing a simple explanation for its transforming potential.
Amplification of MDM2 (also known as HDM2) has been
observed in approximately one-third of human sarcomas that
retain wild-type p53 (Oliner et al., 1992), which indicates that
overexpression of MDM2 is a molecular mechanism by which
cells can inactivate p53 during tumor formation.
Genetic experiments have demonstrated the importance of
the Mdm2-p53 interaction. Mdm2-deficient mice die very
early in development prior to implantation, whereas mice
lacking both p53 and Mdm2 are viable and indistinguishable
from mice lacking only p53 (Montes de Oca Luna et al., 1995;
Jones et al., 1995). Similarly, Zdm2-deficient zebrafish
embryos, generated by injection of antisense morpholinos,
exhibit widespread apoptosis, which leads to developmental
arrest. As in Mdm2-deficient mice, simultaneous inactivation
of Zp53 in Zdm2-deficient zebrafish embryos rescues this
developmental defect (Langheinrich et al., 2002). In addition,
mice possessing a hypomorphic Mdm2 mutation exhibit
defects in thymus development, metabolism, bone marrow
production and intestinal cell production (Mendrysa et al.,
2003). Conditional inactivation of an Mdm2Lox allele in
cardiomyocytes (Grier et al., 2006), neuronal progenitor cells
(Xiong et al., 2006) and smooth muscle cells (SMCs) of the
gastrointestinal (GI) tract (Boesten et al., 2006) leads to p53-
dependent cell death. Finally, conditional expression of p53 in
neuronal progenitor cells and post-mitotic neurons of Mdm2-
null mice leads to dramatic p53 activation and cell death
(Francoz et al., 2006). Mdm2 thus appears to be an essential
p53 antagonist in the developing embryo and in mature
differentiated cells.
Transfection studies suggest that Mdm2 inhibits p53 by
multiple mechanisms. Mdm2 is a RING-finger-containing
protein that acts as an E3 ligase, which is essential for
ubiquitylation and subsequent degradation of p53 (Haupt et al.,
1997; Kubbutat et al., 1997). Recent studies show that Mdm2
is required to maintain p53 at low levels both in proliferating
and in post-mitotic cells (reviewed by Marine et al., 2006).
Genetic evidence supports the notion that constitutive
degradation of p53 in vivo strictly depends on Mdm2. This is
particularly interesting since several other ubiquitin ligases that
target p53, such as Pirh2, Cop-1 or ARF/BP1, have been
discovered and shown to function in an Mdm2-independent
manner (Leng et al., 2003; Dornan et al., 2004; Chen, D. et al.,
2005). However, none of these proteins can sufficiently, if at
all, compensate for loss of Mdm2 function in vivo.
Mdm2 binds to the transactivation domain of p53; this
interaction might also interfere with the recruitment of the
basal transcription machinery and/or essential co-activator(s)
(Thut et al., 1997). Moreover, Mdm2 has been reported to
promote conjugation of NEDD8 to p53, a modification that
The tumor suppressor protein p53 is negatively regulated
by Mdm2, a ubiquitin ligase protein that targets p53 for
degradation. Mdmx (also known as Mdm4) is a relative of
Mdm2 that was identified on the basis of its ability to
physically interact with p53. An increasing body of
evidence, including recent genetic studies, suggests that
Mdmx also acts as a key negative regulator of p53.
Aberrant expression of MDMX could thus contribute to
tumor formation. Indeed, MDMX amplification and/or
overexpression occurs in several diverse tumors. Strikingly,
recent work identifies MDMX as a specific
chemotherapeutic target for treatment of retinoblastoma.
Specific MDMX antagonists should therefore be developed
as a tool to ensure activation of ‘dormant’ p53 activity in
tumors that retain wild-type p53.
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inhibits its transcriptional activity (Xirodimas et al., 2004).
Finally, Mdm2 induces mono-ubiquitylation of histone H2B
surrounding p53-response elements, which results in
transcriptional repression (Minsky and Oren, 2004). Recent
genetic studies are not entirely consistent with a role for Mdm2
in the regulation of p53 transcriptional activity per se, however
(Marine et al., 2006). Further genetic studies, such as knockin
mutations, will be necessary to resolve whether Mdm2
antagonizes p53 only through protein degradation or through
repression of transcriptional activation as well.
Mdmx, an Mdm2-related protein
Mdmx (also known as Mdm4) was originally isolated as a
novel p53-interacting protein from a mouse cDNA expression
library (Shvarts et al., 1996). The human ortholog, MDMX,
was identified later (Shvarts et al., 1997). Both Mdmx and
MDMX interact with p53 in cells, and Mdmx overexpression
inhibits p53-activated transcription (Shvarts et al., 1996).
cDNAs encoding MDMX were independently identified in a
yeast two-hybrid screen for MDM2-associated proteins
(Sharp et al., 1999; Tanimura et al., 1999). Indeed, the two
related proteins interact in vivo. Hetero-oligomerization
between Mdmx and Mdm2 appears to be much more stable
than homo-oligomerization of each protein (Tanimura et al.,
1999). Mdmx is thus implicated in the regulation of the p53-
Mdm2 axis.
MDMX and MDM2 are structurally related proteins of 490
and 491 amino acids, respectively (Fig. 1). The greatest
similarity between the two proteins is at the N-terminus, a
region encompassing the p53-binding domain. The residues
required for interaction with p53 are strictly conserved in
MDM2 and MDMX (Shvarts et al., 1996), and the same
residues in p53 are required for both MDMX-p53 and MDM2-
p53 interactions (Bottger et al., 1999). Another well-conserved
region common to MDMX and MDM2 is a RING-finger
domain, located at the C-terminus of each protein. The
integrity of the RING-finger domain is essential for MDMX-
MDM2 heterodimerization (Sharp et al., 1999; Tanimura et al.,
1999). Both MDM2 and MDMX also contain an additional
zinc-finger domain. The function of this domain is largely
unknown, but recent results suggest that an intact zinc finger,
together with a central acidic domain, is essential for
interaction between MDMX and casein kinase 1 alpha (CK1-
) (Chen, L. et al., 2005b). The central regions of MDM2 and
MDMX show no significant similarity, but both regions are
rich in acidic residues.
The post-translational modifications of Mdmx that have
been characterized to date include phosphorylation,
ubiquitylation and SUMOylation. Ubiquitylation and
phosphorylation are both important factors in regulation of
Mdmx stability and activity (see below). Pan and Chen showed
in transient transfection studies that Mdmx is conjugated with
SUMO-1 on K254 and K379 (Pan and Chen, 2005), but
conversion of K254 and K379 to arginine has no effect on
MdmX function in the assays used by these authors. We have
extended these studies and could demonstrate that endogenous
MDMX is modified by SUMO-2 on K254 and K379 (E.
Meulmeester, M. Groenewoud and A.G.J., unpublished data).
However, the biological relevance of these modifications
remains unclear.
Mdmx, another key gatekeeper of the guardian
Because of its similarity to Mdm2 and its ability to inhibit p53-
induced transcription following overexpression, Mdmx was
hypothesized to act as a negative regulator of p53 (Shvarts et
al., 1996; Migliorini et al., 2002a). This view has been
Journal of Cell Science 120 (3)
Fig. 1. Comparison of the MDM2 and MDMX primary structures. Several functional domains are highlighted. The p53-binding domain, zinc
(Zn) finger and RING finger [containing the nucleolar location signal (NoLS)] are conserved. The percentage identity shared between these
domains is indicated. Although both MDM2 and MDMX contain an acidic domain, no significant conservation of amino acid sequence is
found, and the acidic domain of MDMX is smaller than that of MDM2. Part of the MDMX amino acid sequence (338-407) is shown to indicate
the functional domains and modification sites. Serines (S) indicated in red are validated phosphorylation sites, whereas lysines (K) indicated in
blue are targets for SUMO conjugation. DVPD, caspase-3 cleavage site; NES, nuclear export signal; NLS, nuclear localization signal.
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confirmed by loss-of-function studies in two mutant mouse
lines, which concluded that, similarly to Mdm2, Mdmx acts in
vivo as an essential, non-redundant, negative regulator of p53
during embryonic development. Indeed, inactivation of p53
rescues the developmental defects that otherwise occur in
Mdmx-deficient mice (Parant et al., 2001; Migliorini et al.,
2002b; Finch et al., 2002) (reviewed by Marine and
Jochemsen, 2004).
Unfortunately, because of the early embryonic lethality
associated with Mdm2-null and Mdmx-null mutations, it has
been difficult to assess the physiological contributions of
Mdm2 and Mdmx to the regulation of p53 levels and activity.
However, conditional alleles have recently been developed that
yield further insight into how and in what cell types Mdm2 and
Mdmx regulate p53 (Grier et al., 2002; Steinman and Jones,
2002; Mendrysa et al., 2003; Grier et al., 2006).
To test whether Mdm2 and Mdmx are required to restrain
p53 activity in a single cell type, Xiong et al. conditionally
inactivated both Mdm2 and Mdmx in neuronal progenitors
(Xiong et al., 2006). Meanwhile, Francoz et al. conditionally
expressed p53 in neuronal progenitor cells or in post-mitotic
cells of mice lacking Mdm2 and/or Mdmx (Francoz et al.,
2006). Loss of Mdmx or Mdm2 leads to distinct phenotypes
(see below) but, importantly, all phenotypes disappear in the
absence of p53. Both Mdm2 and Mdmx are thus required to
inhibit p53 activity in the same cell type, and these results
confirm the notion that physiological levels of Mdm2 cannot
compensate for Mdmx loss in vivo, at least in the
abovementioned cell types.
Mdmx has also been conditionally inactivated in
cardiomyocytes (Grier et al., 2006) and SMCs of the GI tract
(Boesten et al., 2006). In contrast to loss of Mdm2, loss of
Mdmx leads to only minor defects in histogenesis and tissue
homeostasis. The data suggest that inhibition of p53 by Mdmx
is required only in a restricted number of cell types and/or
under certain physiological conditions. However, interpretation
of these results is complicated. Even in cells in which Mdmx
function is crucial, such as neuronal progenitor and post-
mitotic cells, in contrast to Mdm2, loss of Mdmx consistently
leads to only a moderate increase in p53 activity in vivo. This
difference can be explained, at least in part, by the fact that p53
activates the transcription of Mdm2 (Barak et al., 1993; Wu et
al., 1993) but not Mdmx. Thus, in the absence of Mdmx, p53
transcriptional activity is enhanced, leading to the stimulation
of the p53-Mdm2 negative feedback loop. Indeed, Mdmx loss
leads to a moderate increase in Mdm2 protein levels in vitro
and an increase in Mdm2 transcription in vivo (Xiong et al.,
2006; Francoz et al., 2006; Toledo et al., 2006). Note also that
overexpression of an Mdm2 transgene rescues the embryonic
lethality associated with Mdmx-deficiency (Steinman et al.,
2005), indicating that high levels of Mdm2 compensate for
Mdmx loss. Thus, increased Mdm2 levels might better
compensate for Mdmx loss in specific cell types, which would
represent an alternative to a more simplistic view of a tissue-
specific function of Mdmx. Nevertheless, at the molecular
level, the difference in the severity of the Mdm2-null and
Mdmx-null phenotypes is probably as a result of the fact that
loss of Mdm2 leads to dramatic accumulation of the p53
protein, whereas loss of Mdmx does not significantly increase
p53 levels in vivo (see below).
The molecular details of the role of Mdmx in the control of
p53 and Mdm2 stability also remain unclear. Mdmx has been
reported to act as a ubiquitin ligase in vitro (Badciong and
Haas, 2002), but Mdmx overexpression in cells does not lead
to p53 ubiquitylation and degradation (Jackson and Berberich,
2000; Stad et al., 2000; Migliorini et al., 2002a). However,
Mdmx might regulate p53 stability indirectly by stabilizing
Mdm2. Indeed, transfection studies suggest that Mdmx
stabilizes Mdm2, perhaps by interfering with its auto-
ubiquitylation (Gu et al., 2002; Stad et al., 2001). Another
report, however, suggests that Mdmx stimulates not only
Mdm2-mediated ubiquitylation of p53 but also Mdm2 self-
ubiquitylation (Linares et al., 2003). p53 levels stay below the
limit of detection when it is conditionally expressed in
progenitor and post-mitotic neuronal cells of Mdmx-null mice
(Francoz et al., 2006). Similarly, p53 is not detectable in E10.5
neural progenitor cells in which Mdmx is conditionally
inactivated. By contrast, clear p53 staining is observed in
Mdm2-deficient cells at the same stage of development (Xiong
et al., 2006). Moreover, loss of both Mdm2 and Mdmx does not
lead to any further increase in p53 levels compared with loss
of Mdm2 alone. This suggests that Mdmx does not participate
in the regulation of p53 stability independently of Mdm2
(Francoz et al., 2006). However, whether it does so in an
Mdm2-dependent manner remains unclear. The analysis of
mice encoding a mutant p53 that lacks the proline-rich domain
(p53P) also enabled evaluation of Mdmx function (Toledo et
al., 2006). This hypomorphic p53 mutant can fully rescue
Mdmx deficiency. The consequences of Mdmx loss can
therefore be observed in a compromised p53 context in the
absence of Cre expression. In the absence of Mdmx, the
transcription of Mdm2 is stimulated to some extent, leading to
slightly increased Mdm2 protein levels. Mdmx thus does not
seem to affect Mdm2 protein stability significantly.
The contribution of Mdmx to the regulation of p53
transcriptional activity has become clearer. Genetic evidence
indicates that Mdmx inhibits p53 transcriptional activity
independently of Mdm2. Loss of Mdmx in cells lacking Mdm2
causes an increase in p53 activity in cultured mouse embryonic
fibroblasts (MEFs) without a concomitant increase in p53
levels (Francoz et al., 2006). Analyses of p53P regulation by
Mdm2 and Mdmx produced similar results (Toledo et al.,
2006). p53 interacts with the p300 histone acetyltransferase
and this interaction appears to be essential for p53-dependent
activation of the promoter of the p53-target gene p21 (Liu et
al., 2003). p53 itself is acetylated by p300 on several lysine
residues, and this modification is thought to increase its
transcriptional activity (Prives and Manley, 2001).
Interestingly, Mdmx decreases p300-mediated acetylation of
p53 (Danovi et al., 2004; Sabbatini and McCormick, 2002),
and endogenous p53 acetylation is increased in Mdmx-null
cells (Migliorini et al., 2002b). Regardless, the exact nature of
the mechanism through which Mdmx attenuates p53
transcriptional activity awaits further investigation. Moreover,
one additional caveat is that all these studies were performed
in cultured cells (MEFs) in which Mdmx protein levels were
not examined, mainly owing to lack of high-affinity antibodies.
The stability of Mdmx could be affected by manipulation of
Mdm2 levels because Mdm2 can ubiquitylate Mdmx, which
leads to its degradation (discussed below). In cells lacking both
p53 and Mdm2, the Mdmx protein levels are increased
compared with cells lacking p53 only (Meulmeester et al.,
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2005). It will, therefore, be essential in the future to assess
endogenous Mdmx protein levels in such experiments.
Mdmx and Mdm2 thus appear to cooperate to antagonize
p53 (Fig. 2). This has been confirmed in various in vivo
settings. Mice lacking both Mdm2 and Mdmx in the CNS
exhibit a phenotype that is more severe and appears earlier than
that of Mdm2-null mice (Xiong et al., 2006). Similarly, the
extent of p53-mediated apoptosis is significantly greater in the
neuroepithelium and in post-mitotic cells in mice lacking both
Mdm2 and Mdmx than in mice lacking Mdm2 alone (Francoz
et al., 2006). The cooperation of Mdm2 and Mdmx to limit p53
activity is therefore irrespective of the proliferation and/or
differentiation status of the cells.
Both Mdm2 and Mdmx have been implicated in regulation
of the stability and/or activity of several other proteins that
control cell proliferation, such as the retinoblastoma protein
pRb, the heterodimer E2F1-DP1, Numb and Smads (Ganguli
and Wasylyk, 2003; Marine and Jochemsen, 2005). However,
the relevance of these interactions has not been firmly
established genetically. Moreover, several lines of evidence
argue against p53-independent functions of Mdm2 and Mdmx
under physiological conditions. They do not exclude the
possibility, however, that supra-physiological expression levels
of these two proteins affect the activity of other proteins and
p53-independent pathways. This possibility is interesting,
since both proteins are aberrantly expressed in several human
primary tumors (see below).
Regulation of Mdmx expression and activity
As mentioned above, p53 is stabilized following cellular
stress, such as DNA damage. Many mechanisms have been
proposed (mostly involving phosphorylation) to regulate
Mdm2-p53 interactions and/or Mdm2 activity (reviewed by
Wahl, 2006). Only recently has insight into Mdmx regulation
after DNA damage been obtained. In contrast to Mdm2, there
is no evidence so far that transcription of Mdmx is affected by
DNA damage, mitogens or any other cellular stress. Mdmx
instead appears to be regulated mainly at the protein level.
Several groups have shown that Mdm2 can bind to and
ubiquitylate Mdmx to stimulate its proteasome-dependent
degradation (Pan and Chen, 2003; de Graaf et al., 2003; Kawai
et al., 2003).
Interestingly, in normal proliferating cells, MDM2 does not
play a major role in regulation of MDMX stability. The MDMX
protein is very stable, and knocking down MDM2 in cultured
cells has little effect on the levels of MDMX (reviewed by
Marine and Jochemsen, 2005). However, following DNA
damage, MDMX levels rapidly decline in an MDM2-dependent
manner. The Ataxia telangiectasia mutated (ATM) protein and
checkpoint kinase 2 (Chk2) are key regulators of biological
responses to DNA damage. Efficient degradation of MDMX
following DNA damage requires ATM-dependent
phosphorylation on S342 and S367 by Chk2 and S403 by ATM
(Pereg et al., 2005; Chen, L. et al., 2005a; Okamoto et al., 2005;
Pereg et al., 2006). Furthermore, UVC treatment results in Chk1-
mediated phosphorylation of S367 (Jin et al., 2006).
Phosphorylation of MDMX reduces its affinity for the
deubiquitylating enzyme (DUB) HAUSP/USP7 (Meulmeester et
al., 2005). Expression of HAUSP is essential for maintenance of
both MDM2 and MDMX protein levels (Cummins et al., 2004;
Li et al., 2004). MDM2 destabilization following DNA damage
(Stommel and Wahl, 2004) is also the result of decreased
HAUSP binding, whereas binding of p53 to HAUSP is not
affected (Meulmeester et al., 2005). The destabilization of both
MDMX and MDM2 is essential for proper p53 activation
following DNA damage. The mechanism by which MDMX
phosphorylations affect the MDMX-HAUSP interaction has not
been elucidated. Clearly, loss of HAUSP binding might not be
the only mechanism involved. For example, phosphorylation of
both S342 and S367 creates binding sites for 14-3-3 protein.
Interaction of 14-3-3 with MDMX is necessary for DNA-
damage-induced nuclear accumulation and degradation of
MDMX (LeBron et al., 2006; Pereg et al., 2006). It might also,
however, affect binding to HAUSP.
Basal phosphorylation of Mdmx on Ser96 and Ser289 by
CDK1 and CK1-, respectively, has also been reported (Elias
et al., 2005; Chen, L. et al., 2005b). Phosphorylation of Ser96
is proposed to regulate Mdm2 localisation, whereas the CK1-
-mediated phosphorylation stimulates the Mdmx-p53
interaction by an unknown mechanism. Mdmx thus appears to
be regulated primarily by post-translational modifications that
affect its stability, subcellular localization and protein-protein
interactions.
Journal of Cell Science 120 (3)
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Target genes
Mdm2
Mdmx
p21
Ptprv
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Fig. 2. A model for cooperative control of the p53 pathway by Mdm2
and Mdmx. In the absence of stress signals, the primary function of
Mdm2 is to maintain p53 at low levels, whereas Mdmx contributes to
the overall inhibition of p53 independently of Mdm2. Mdmx inhibits
p53 transcriptional activity, whereas the contribution of Mdm2 to the
regulation of p53 transcriptional activity per se is still unclear and a
matter of debate. The role of Cop-1 and Pirh2 in the regulation of
p53 levels and activity in vivo is unclear, but recent data suggest that,
if they participate in the regulation of this pathway, they can only do
so in an Mdm2-dependent manner. See text for details.
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MDMX contributes to tumorigenesis
Disruption of the p53 tumor suppressor pathway is as a result
of mutation of the p53 gene in approximately 50% of cases.
Tumors retaining wild-type p53 are thought to have defects
either in effector target genes or in the expression of p53
regulators. One of the best examples of the latter class is
MDM2, levels of which can be increased by gene
amplification, enhanced transcription or increased translation.
Several studies now implicate MDMX in tumor formation. A
study on a large series of gliomas revealed that MDMX
is amplified/overexpressed in 5/208 tumor samples
(Riemenschneider et al., 1999) and that MDMX is the common
amplified gene in the large amplicons (Riemenschneider et al.,
2003). Furthermore, in approximately 30% of the tumor cell
lines tested MDMX is either overexpressed or alternatively
transcribed, and in general this correlates with the presence of
wild-type p53 (Ramos et al., 2001). A recent analysis of a large
series of tumors also revealed overexpression of MDMX in a
significant percentage of several tumor types – for example,
19% of breast carcinomas (Danovi et al., 2004). In all cases,
amplification of MDMX correlated with wild-type p53 status
and lack of MDM2 amplification.
The importance of enhanced MDMX expression has been
tested in the MCF-7 breast tumor cell line, which contains
wild-type p53. Knocking down endogenous MDMX increases
expression of p21, a p53-responsive gene product that
negatively regulates progression through the cell cycle, without
a significant increase in p53 levels. Colony assays showed that
knocking down MDMX blocks proliferation of MCF-7 cells
unless p53 levels are simultaneously decreased. Constitutive
expression of Mdmx immortalizes MEFs in the absence of p53
mutation or loss of expression of ARF, a nucleolar protein that
antagonizes Mdm2 functions (Sherr and Weber, 2000).
Furthermore, Mdmx prevents oncogenic-Ras-induced
premature senescence, and cells expressing Mdmx and
activated Ras (RasV12) are oncogenic in nude mice (Danovi et
al., 2004). MDMX thus functions as an oncogene when
constitutively overexpressed, which can act as an alternative to
p53 mutation in human tumors.
Many tumors contain aberrantly and/or alternatively spliced
MDM2 variants. The effects of these variants are still
unknown, but their expression is more common in high-grade
than in low-grade tumors (Bartel et al., 2004). A systematic
analysis of MDMX splice variants in large tumor sets is still
lacking. However, two variants have been identified and
partially characterized. The MDMX-S variant comprises only
the p53-binding domain and a few alternative C-terminal
amino acids. It is detected both in untransformed and
transformed cells, and its expression is elevated when cells are
stimulated to enter S-phase (Rallapalli et al., 1999). Owing to
a higher affinity than full-length MDMX for p53 and to its
increased nuclear localization, MDMX-S appears to be a very
efficient inhibitor of p53 (Rallapalli et al., 1999; Rallapalli et
al., 2003). MDMX-S is also more stable than MDMX, possibly
because it can no longer interact with MDM2 and is, therefore,
protected from MDM2-mediated degradation. Interestingly, an
elevated MDMX-S/MDMX ratio has been reported in high-
grade gliomas (Riemenschneider et al., 2003). Moreover,
analysis of soft-tissue sarcomas indicated that high MDMX-S
levels correlate with decreased survival and an increased risk
of tumor-related death (Bartel et al., 2005).
Another splice variant, MDMX211, results from splicing
between the exon 2 donor site and a cryptic splice acceptor site
within exon 11 (Giglio et al., 2005). The resulting protein lacks
the p53-binding domain but retains the RING-finger domain.
Transfection and RNAi studies indicate that this protein has
oncogenic activity possibly as a result of stabilization of
MDM2. Although MDMX211 variant has been identified in
2/16 analyzed non-small-cell lung tumors, further studies are
needed to establish its significance in human cancer.
MDMX as a drug target in retinoblastoma
Retinoblastoma is a rare childhood cancer of the retina that
initiates in utero during fetal development because of
inactivation of the RB1 gene (Dyer and Harbour, 2006).
Although the initiating genetic event (biallelic inactivation of
RB1) is well established, the subsequent genetic events that
contribute to retinoblastoma progression have not been well
characterized. The status of the p53 pathway has been a topic
of considerable debate in the field. Early studies on human
tumors demonstrated that p53 is wild-type in retinoblastoma
(Kato et al., 1996). However, exogenous p53 can induce cell
death in retinoblastoma cell lines (Nork et al., 1997). In HPV-
E7 transgenic mouse models of retinoblastoma, tumor
development is greatly enhanced when p53 is inactivated
(Howes et al., 1994). Recently, Zang et al. developed the first
knockout mouse model of retinoblastoma (Zhang et al., 2004)
by conditionally inactivating Rb1 in the developing retina of
p107–/– mice. As in the HPV-E7 transgenic mouse models,
inactivation of p53 in retinal progenitor cells lacking Rb1 and
p107 leads to an aggressive invasive form of retinoblastoma in
mice that more faithfully recapitulates the human disease (Dyer
et al., 2005). Inactivation of the p53 pathway is therefore likely
to be an important step in retinoblastoma progression, but the
p53 gene itself remains intact.
BAC-CGH, fluorescence in situ hybridization (FISH) and
immunohistochemistry (IHC) studies reveal an increased
MDMX copy number in 65% of human retinoblastomas, and
MDM2 is amplified in an additional 10% of these tumors
(Laurie et al., 2006). Genetic amplification of MDMX
correlates with increased mRNA and protein levels and
suppression of p53 target genes such as p21. MDMX regulates
cell death and cell cycle exit in cultured retinoblastoma cells
in a p53-dependent manner. Moreover, ectopic expression of
MDMX in mouse Rb-null p107-null retinal progenitor cells
leads to a reduction in p53-mediated apoptosis and clonal
expansion of tumor cells. Similar studies of human fetal retinae
demonstrate that ectopic expression of MDMX rescues p53-
mediated cell death as a result of activation of the ARF
oncogenic stress response pathway following RB1 gene
inactivation. These experiments clearly show that the p53
pathway is suppressed in retinoblastoma cells following
biallelic inactivation of RB1 and that a majority of tumors
inactivate the p53 pathway through MDMX gene amplification
(Fig. 3). In addition, they show that retinoblastoma does not
arise from an intrinsically death-resistant cell as previously
believed (Dyer and Bremner, 2005).
These findings not only challenge the long-standing belief
that retinoblastoma is the exception to the general principle that
the Rb and p53 pathways must be inactivated in cancer, but
also provide a specific target for chemotherapy. Nutlin-3, a
small-molecule inhibitor of the MDM2-p53 interaction
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(Vassilev et al., 2004), was shown to act primarily through
MDM2 even in cells expressing high levels of MDMX (Patton
et al., 2006). However, we have recently shown that nutlin-3
also binds to MDMX, even if it does so with a 40-fold lower
affinity than for MDM2 (Laurie et al., 2006). This is consistent
with structural and functional studies suggesting that MDM2
antagonists may not be optimal as MDMX antagonists (Bottger
et al., 1999; McCoy et al., 2003). Nevertheless, nutlin-3 can
induce p53-mediated cell death in Mdm2-deficient MEFs in a
manner that is dependent on Mdmx. Moreover, nutlin-3
reduces the MDMX-p53 interaction and efficiently kills
retinoblastoma cells (Laurie et al., 2006). Furthermore,
combining nutlin-3 with topotecan synergistically increases
tumor cell killing through the p53 pathway. Given the efficacy
of such a treatment in rodents, we propose that subconjunctival
administration of these two drugs could achieve the same
synergistic effect in patients without causing the side effects
associated with prolonged systemic exposure. Not only is
retinoblastoma a good model for suppression of p53-mediated
cell death by MDMX amplification but it is an ideal system to
study local delivery of chemotherapy targeted to the ARF-
MDM2/MDMX-p53 pathway.
Concluding remarks and perspectives
Mdmx primarily inhibits p53 by interfering with its
transcriptional activity. Even if it is now clear that direct
interaction between Mdmx and p53 appears essential, the
molecular mechanism by which Mdmx regulates p53 activity
has not been fully elucidated and should be. Mdmx not only
interacts with p53 but also heterodimerizes with Mdm2. The
relevance of this interaction in vivo has to be further examined
since the existing mouse models have failed, so far, to support
most transfection studies, which indicates that this interaction
regulates Mdm2 and Mdmx protein stability. In view of its high
degree of sequence conservation and its similarity with Mdm2,
it is intriguing that the RING-finger domain of Mdmx appears
incapable of inducing ubiquitylation and subsequent
degradation of p53. It will be interesting to assess whether or
not this domain is required only for the formation of Mdmx-
Mdm2 complexes or if it is required for ubiquitylation of other
substrates. In this context, it would be worth checking whether
this domain can promote binding of Mdmx to E2 ubiquityl
conjugases. Another major unknown is the relative abundance
of the Mdm2 and Mdmx proteins and the stoichiometry of the
different complexes that can be formed, such as p53-Mdm2,
p53-Mdmx, Mdm2-Mdmx and possibly p53-Mdm2-Mdmx, in
normal cells and cells under stress. In order to resolve this
important issue, new tools will have to be generated, such as
high-affinity anti-Mdmx antibodies and more elaborate mouse
models – for instance, Mdm2 and Mdmx alleles expressing
tagged proteins from the respective endogenous promoters.
Knockin mutations should also be used to test the relevance of
the ATM- and Chk2-phosphorylation sites described above.
There is now clear genetic evidence indicating that Mdmx
contributes to the regulation of p53 independently of Mdm2
and that both proteins act synergistically to keep p53 in check
(Francoz et al., 2006; Marine et al., 2006). Thus, activation of
‘dormant’ p53 tumor suppressor activity in tumors with wild-
type p53 is expected to be more efficient if one uses specific
antagonists that can target both MDM2 and MDMX. Since
nutlin-3 has only a poor affinity for Mdmx, we propose that
new, specific Mdmx antagonists should be developed.
Alternatively, if nutlin-3 can be delivered locally at a high
enough concentration to inhibit both MDM2 and MDMX, then
this treatment may be sufficient. A particularly clear
illustration of the latter approach is the efficacy with which
retinoblastoma development is impaired in a rat xenograft
model upon subconjunctival delivery of nutlin-3. Moreover, by
combining MDM2/MDMX antagonists with drugs that induce
a p53 response through DNA damage (e.g. topotecan) this anti-
tumor effect may be further enhanced.
One of the most common ways that the p53 pathway is
inactivated in retinoblastomas is by increased MDMX
expression through gene amplification. It is intriguing that the
frequency of MDMX amplification is high in retinoblastoma
compared with other tumor types (Danovi et al., 2004). This
observation may be explained by the difference in the ability
of ARF to bind to MDM2 and MDMX. Biochemical studies
have shown that ARF can bind to MDM2 but not MDMX
(Wang et al., 2001). Considering that ARF is directly regulated
by RB1 (Aslanian et al., 2004), retinal cells lacking RB1 may
have a greater degree of induction of ARF than tumors initiated
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p53MDM2
RB1
ARFE2Fs Cell death
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ARFE2Fs Cell death
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A  Loss of RB1
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Fig. 3. Interactions between Rb, MDMX and p53
during retinoblastoma formation. (A) Biallelic
inactivation of the RB1 gene is the initiating
oncogenic event in retinoblastoma. As a
consequence, the activity of transcription factors of
the E2F family is unleashed, leading to increased S-
phase entry and induction of ARF expression. ARF
is induced in response to oncogenic stress and a
direct E2F3a transcription target. ARF functions as
an Mdm2 antagonist and therefore activates the p53
pathway. High ARF expression was indeed recently
detected in RB1-deficient retinoblasts and, as a
consequence, a high proportion of these cells
undergo p53-mediated apoptosis. (B) The p53
pathway is suppressed during the formation of
retinoblastoma and the majority of tumors
inactivate this pathway through selective
amplification and/or overexpression of MDMX.
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by other disruptions in the Rb pathway – for instance, those
involving p16, cyclin D1 or CDK4 (Sherr and McCormick,
2002). MDM2 amplification should therefore not lead to
efficient inhibition of the p53 pathway in RB1-deficient retinal
cells. In contrast, despite high levels of ARF, MDMX
amplification would be expected to efficiently block the p53
cell death pathway in retinoblastoma because ARF does not
bind MDMX. Additional experiments, including the
generation of conditional Mdm2 and Mdmx mouse models,
will be necessary to test further this hypothesis.
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